SCHOTT Pharma KGaA Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Reisse
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.8yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | €150m |
| Sep 30 2025 | n/a | n/a | €146m |
| Jun 30 2025 | n/a | n/a | €148m |
| Mar 31 2025 | n/a | n/a | €148m |
| Dec 31 2024 | n/a | n/a | €135m |
| Sep 30 2024 | €1m | €397k | €150m |
| Jun 30 2024 | n/a | n/a | €150m |
| Mar 31 2024 | n/a | n/a | €135m |
| Dec 31 2023 | n/a | n/a | €158m |
| Sep 30 2023 | €839k | €356k | €152m |
| Jun 30 2023 | n/a | n/a | €143m |
| Sep 30 2022 | €793k | €332k | €125m |
Compensation vs Market: Insufficient data to establish whether Andreas's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Andreas's compensation has increased by more than 20% in the past year.
CEO
Andreas Reisse (64 yo)
Mr. Andreas Reisse is Chairperson of Management Board & CEO of SCHOTT Pharma Management AG the GP of SCHOTT Pharma AG & Co. KGaA from July 15, 2022. He studied industrial engineering at the University of K...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Deputy Chairman of Supervisory Board | 1.2yrs | no data | no data | |
| Independent Chairman of Supervisory Board | 3yrs | €80.00k | no data | |
| Independent Member of Supervisory Board | 3yrs | €60.00k | no data | |
| Independent Member of Supervisory Board | 3yrs | €50.00k | no data | |
| Employee Representative Member of Supervisory Board | 3yrs | €40.00k | no data |
Experienced Board: SHTP.Y's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 18:07 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Christian Ehmann | Berenberg |